AU2010310688A1 - Method of using non-rare cells to detect rare cells - Google Patents
Method of using non-rare cells to detect rare cells Download PDFInfo
- Publication number
- AU2010310688A1 AU2010310688A1 AU2010310688A AU2010310688A AU2010310688A1 AU 2010310688 A1 AU2010310688 A1 AU 2010310688A1 AU 2010310688 A AU2010310688 A AU 2010310688A AU 2010310688 A AU2010310688 A AU 2010310688A AU 2010310688 A1 AU2010310688 A1 AU 2010310688A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- marker
- cells
- ctcs
- rare
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 160
- 210000004027 cell Anatomy 0.000 claims abstract description 396
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims abstract description 251
- 238000004458 analytical method Methods 0.000 claims abstract description 48
- 238000013480 data collection Methods 0.000 claims abstract description 8
- 239000003550 marker Substances 0.000 claims description 136
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 201000011510 cancer Diseases 0.000 claims description 52
- 210000000265 leukocyte Anatomy 0.000 claims description 52
- 102000011782 Keratins Human genes 0.000 claims description 37
- 108010076876 Keratins Proteins 0.000 claims description 37
- 238000009826 distribution Methods 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 238000003384 imaging method Methods 0.000 claims description 29
- 230000001413 cellular effect Effects 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 21
- 238000003908 quality control method Methods 0.000 claims description 19
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 18
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 18
- 238000010186 staining Methods 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 11
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 11
- 238000004393 prognosis Methods 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 9
- 230000004043 responsiveness Effects 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000006727 cell loss Effects 0.000 claims description 4
- 239000002771 cell marker Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 36
- 238000013459 approach Methods 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 6
- 230000009467 reduction Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 72
- 210000004369 blood Anatomy 0.000 description 41
- 239000008280 blood Substances 0.000 description 41
- 238000003556 assay Methods 0.000 description 36
- 238000012512 characterization method Methods 0.000 description 20
- 238000012545 processing Methods 0.000 description 16
- 210000002919 epithelial cell Anatomy 0.000 description 15
- 210000002307 prostate Anatomy 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 14
- 239000000306 component Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 210000000805 cytoplasm Anatomy 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 238000000386 microscopy Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000000601 blood cell Anatomy 0.000 description 6
- 230000003211 malignant effect Effects 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
- 239000013610 patient sample Substances 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 238000007747 plating Methods 0.000 description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 3
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 3
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 3
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- -1 cMET Proteins 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000004987 nonapoptotic effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 102000003998 progesterone receptors Human genes 0.000 description 3
- 108090000468 progesterone receptors Proteins 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010008707 Mucin-1 Proteins 0.000 description 2
- 102000007298 Mucin-1 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000002358 circulating endothelial cell Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000003312 immunocapture Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 102000030797 EphB4 Receptor Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100031671 Homeobox protein CDX-2 Human genes 0.000 description 1
- 102100027893 Homeobox protein Nkx-2.1 Human genes 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 101000632178 Homo sapiens Homeobox protein Nkx-2.1 Proteins 0.000 description 1
- 101000845269 Homo sapiens Transcription termination factor 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 101100226013 Mus musculus Ercc1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 230000032978 apoptotic nuclear change Effects 0.000 description 1
- 239000012122 aqueous mounting media Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000006571 choroid plexus carcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002488 pyknotic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Image Processing (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016203462A AU2016203462B2 (en) | 2009-10-21 | 2016-05-26 | Method of using non-rare cells to detect rare cells |
| AU2018247290A AU2018247290A1 (en) | 2009-10-21 | 2018-10-11 | Method of using non-rare cells to detect rare cells |
| AU2021202220A AU2021202220A1 (en) | 2009-10-21 | 2021-04-13 | Method of using non-rare cells to detect rare cells |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25378709P | 2009-10-21 | 2009-10-21 | |
| US61/253,787 | 2009-10-21 | ||
| PCT/US2010/053431 WO2011050103A1 (en) | 2009-10-21 | 2010-10-20 | Method of using non-rare cells to detect rare cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203462A Division AU2016203462B2 (en) | 2009-10-21 | 2016-05-26 | Method of using non-rare cells to detect rare cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2010310688A1 true AU2010310688A1 (en) | 2012-05-17 |
Family
ID=43900673
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010310688A Abandoned AU2010310688A1 (en) | 2009-10-21 | 2010-10-20 | Method of using non-rare cells to detect rare cells |
| AU2016203462A Active AU2016203462B2 (en) | 2009-10-21 | 2016-05-26 | Method of using non-rare cells to detect rare cells |
| AU2018247290A Abandoned AU2018247290A1 (en) | 2009-10-21 | 2018-10-11 | Method of using non-rare cells to detect rare cells |
| AU2021202220A Abandoned AU2021202220A1 (en) | 2009-10-21 | 2021-04-13 | Method of using non-rare cells to detect rare cells |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016203462A Active AU2016203462B2 (en) | 2009-10-21 | 2016-05-26 | Method of using non-rare cells to detect rare cells |
| AU2018247290A Abandoned AU2018247290A1 (en) | 2009-10-21 | 2018-10-11 | Method of using non-rare cells to detect rare cells |
| AU2021202220A Abandoned AU2021202220A1 (en) | 2009-10-21 | 2021-04-13 | Method of using non-rare cells to detect rare cells |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20120276555A1 (enExample) |
| EP (3) | EP2491395B1 (enExample) |
| JP (3) | JP6352588B2 (enExample) |
| CN (3) | CN107422127A (enExample) |
| AU (4) | AU2010310688A1 (enExample) |
| CA (1) | CA2778328C (enExample) |
| ES (2) | ES2661735T3 (enExample) |
| WO (1) | WO2011050103A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107422127A (zh) | 2009-10-21 | 2017-12-01 | 斯克里普斯研究所 | 用非稀有细胞检测稀有细胞的方法 |
| EP2543999A4 (en) * | 2010-03-05 | 2016-03-30 | Konica Minolta Holdings Inc | CELL DETECTION METHOD AND CELL DETECTION SYSTEM |
| JP5916991B2 (ja) * | 2010-11-09 | 2016-05-11 | オリンパス株式会社 | 遺伝子異常細胞の解析方法 |
| CN103782170A (zh) * | 2011-07-07 | 2014-05-07 | 斯克里普斯健康机构 | 分析心血管病症的方法及其用途 |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| WO2013109944A1 (en) * | 2012-01-18 | 2013-07-25 | The Trustees Of The University Of Pennsylvania | Methods for assessing risk for cancer using biomarkers |
| ES2724232T3 (es) | 2012-01-24 | 2019-09-09 | Pfizer | Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| AU2014249011A1 (en) * | 2013-03-11 | 2015-09-24 | Roche Diagnostics Hematology, Inc. | Imaging blood cells |
| EP2969177A1 (en) | 2013-03-15 | 2016-01-20 | Massachusetts Institute of Technology | Deposition and imaging of particles on planar substrates |
| US10115034B2 (en) * | 2013-05-01 | 2018-10-30 | Life Technologies Holdings Pte Limited | Method and system for projecting image with differing exposure times |
| US10225483B1 (en) * | 2013-05-01 | 2019-03-05 | Pierce Biotechnology, Inc. | Method and system for projecting image with differing exposure times |
| JP6453592B2 (ja) | 2013-09-25 | 2019-01-16 | アークレイ株式会社 | 血液検体の処理方法 |
| US20160266127A1 (en) | 2013-09-30 | 2016-09-15 | Peter Kuhn | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients |
| EP3967770B1 (en) * | 2013-10-21 | 2023-12-06 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US20160305958A1 (en) * | 2013-12-09 | 2016-10-20 | The Scripps Research Institute | Methods for the detection and quantification of circulating endothelial cells |
| US10147180B2 (en) | 2013-12-19 | 2018-12-04 | Axon Dx, Llc | Cell detection, capture and isolation methods and apparatus |
| WO2015112960A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc) |
| WO2015112955A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EA201691505A1 (ru) * | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) |
| ES2868077T3 (es) * | 2014-01-30 | 2021-10-21 | Epic Sciences Inc | Diagnóstico mediante células tumorales circulantes para biomarcadores predictivos de la resistencia a las terapias selectivas del receptor de andrógenos (RA) |
| EA201691497A1 (ru) * | 2014-01-31 | 2017-01-30 | Эпик Сайенсиз, Инк. | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| EP3140656B1 (en) * | 2014-05-09 | 2021-02-17 | The Scripps Research Institute | Compositions and methods for fluid biopsy of melanoma |
| CN107250796B (zh) * | 2014-09-25 | 2020-10-23 | 艾匹克科学公司 | 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断 |
| WO2016049658A1 (en) * | 2014-09-26 | 2016-03-31 | The Regents Of The University Of California | Method of assessing disease condition of cancer |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| EP3252469A4 (en) * | 2015-01-29 | 2017-12-06 | Konica Minolta, Inc. | Method for simultaneous detection of blood cells having interacting molecules |
| JP6815331B2 (ja) * | 2015-04-21 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| US20180155794A1 (en) * | 2015-05-29 | 2018-06-07 | Epic Sciences, Inc. | Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc) |
| US20180328848A1 (en) * | 2015-11-04 | 2018-11-15 | Axon Dx, Llc | Cell detection, capture, analysis, aggregation, and output methods and apparatus |
| US11371982B2 (en) | 2016-01-19 | 2022-06-28 | Tosoh Corporation | Method of predicting patient prognosis using rare cells |
| US9739783B1 (en) * | 2016-03-15 | 2017-08-22 | Anixa Diagnostics Corporation | Convolutional neural networks for cancer diagnosis |
| US9934364B1 (en) | 2017-02-28 | 2018-04-03 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US10360499B2 (en) | 2017-02-28 | 2019-07-23 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| US11164082B2 (en) | 2017-02-28 | 2021-11-02 | Anixa Diagnostics Corporation | Methods for using artificial neural network analysis on flow cytometry data for cancer diagnosis |
| CN108646034B (zh) * | 2018-07-03 | 2020-10-23 | 珠海圣美生物诊断技术有限公司 | 细胞群中的稀有细胞判读方法 |
| CN111079579B (zh) * | 2019-12-02 | 2023-07-25 | 英华达（上海）科技有限公司 | 细胞图像的识别方法、装置以及系统 |
| KR20220010132A (ko) | 2020-07-17 | 2022-01-25 | 주식회사 엘지에너지솔루션 | 고로딩 전극을 위한 집전체용 시트의 압연 방법 및 고로딩 전극 |
| US20230245478A1 (en) * | 2020-07-30 | 2023-08-03 | Hamamatsu Photonics K.K. | Assessment device, assessment method, assessment program, and recording medium |
| CN113567672A (zh) * | 2021-07-26 | 2021-10-29 | 江南大学附属医院 | 一种检测腹水或腹腔灌洗液中癌细胞的试剂盒 |
| WO2023107566A1 (en) * | 2021-12-07 | 2023-06-15 | Epic Sciences, Inc. | Enhanced characterization of breast cancer |
| CN114910455B (zh) * | 2022-05-06 | 2025-06-20 | 马海燕 | 一种稀有单细胞识别轮廓的可视化的方法 |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9233698A (en) | 1997-11-22 | 1999-06-17 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer cells and/or hematologic progenitor cells in whole blood |
| US6197523B1 (en) | 1997-11-24 | 2001-03-06 | Robert A. Levine | Method for the detection, identification, enumeration and confirmation of circulating cancer and/or hematologic progenitor cells in whole blood |
| US20010018058A1 (en) | 1997-12-24 | 2001-08-30 | Reed Steven G. | Compounds for immunotherapy and diagnosis of breast cancer and methods for their use |
| US8192994B2 (en) | 1998-02-10 | 2012-06-05 | Angros Lee H | Method of applying a biological specimen to an analytic plate |
| BR9907852A (pt) | 1998-02-12 | 2000-10-24 | Immunivest Corp | Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes |
| EP1078257A4 (en) | 1998-05-09 | 2007-07-18 | Iconisys Inc | METHOD AND APPARATUS FOR COMPUTER-ASSISTED DIAGNOSIS OF RARE CELLS, INCLUDING FETAL CELLS |
| AU2876900A (en) | 1999-02-10 | 2000-08-29 | Cell Works Inc. | Class characterization of circulating cancer cells isolated from body fluids andmethods of use |
| AU2001266748B2 (en) * | 2000-06-08 | 2007-01-04 | The Regents Of The University Of California | Visual-servoing optical microscopy |
| US7546210B2 (en) * | 2000-06-08 | 2009-06-09 | The Regents Of The University Of California | Visual-servoing optical microscopy |
| US7033832B2 (en) | 2000-10-13 | 2006-04-25 | University Of Medicine And Dentistry Of New Jersey | Endothelial cell—cell cohesion |
| US20020187485A1 (en) | 2000-10-25 | 2002-12-12 | Jakobsen Mogens Hausteen | Open substrate platforms suitable for analysis of biomolecules |
| US6701197B2 (en) | 2000-11-08 | 2004-03-02 | Orbotech Ltd. | System and method for side to side registration in a printed circuit imager |
| EP1666881B1 (en) | 2001-05-04 | 2010-02-17 | Biosite Incorporated | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| US20080009019A1 (en) * | 2001-06-13 | 2008-01-10 | Smithkline Beecham Corporation | High throughput method for screening candidate compounds for biological activity |
| WO2003019141A2 (en) * | 2001-08-23 | 2003-03-06 | Immunivest Corporation | Analysis of circulating tumor cells, fragments, and debris |
| US7863012B2 (en) | 2004-02-17 | 2011-01-04 | Veridex, Llc | Analysis of circulating tumor cells, fragments, and debris |
| US7943093B2 (en) | 2001-12-12 | 2011-05-17 | Erie Scientific Company | Cover slip |
| WO2003069421A2 (en) * | 2002-02-14 | 2003-08-21 | Immunivest Corporation | Methods and algorithms for cell enumeration in a low-cost cytometer |
| US7305112B2 (en) | 2002-10-15 | 2007-12-04 | The Scripps Research Institute | Method of converting rare cell scanner image coordinates to microscope coordinates using reticle marks on a sample media |
| US7113624B2 (en) | 2002-10-15 | 2006-09-26 | Palo Alto Research Center Incorporated | Imaging apparatus and method employing a large linear aperture |
| US7282180B2 (en) * | 2003-07-02 | 2007-10-16 | Immunivest Corporation | Devices and methods to image objects |
| US7372985B2 (en) * | 2003-08-15 | 2008-05-13 | Massachusetts Institute Of Technology | Systems and methods for volumetric tissue scanning microscopy |
| WO2005100999A2 (en) * | 2004-04-08 | 2005-10-27 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
| WO2006041453A1 (en) | 2004-09-30 | 2006-04-20 | Immunivest Corporation | Circulating tumor cells (ctc’s): apoptotic assessment in prostate cancer patients |
| EP2278383A1 (en) * | 2004-11-24 | 2011-01-26 | Battelle Memorial Institute | A test tube handling apparatus |
| US7280261B2 (en) | 2004-12-20 | 2007-10-09 | Palo Alto Research Center Incorporated | Method of scanning and light collection for a rare cell detector |
| US20090081688A1 (en) * | 2005-06-20 | 2009-03-26 | Advanced Cell Diagnostics | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations |
| US20070009389A1 (en) | 2005-07-08 | 2007-01-11 | Antti Seppo | Slide deposition chamber |
| US9134237B2 (en) | 2005-09-20 | 2015-09-15 | Janssen Diagnotics, LLC | High sensitivity multiparameter method for rare event analysis in a biological sample |
| US20090317836A1 (en) * | 2006-01-30 | 2009-12-24 | The Scripps Research Institute | Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject |
| US8337755B2 (en) * | 2006-03-13 | 2012-12-25 | Veridex, Llc | Operator independent programmable sample preparation and analysis system |
| US20080076727A1 (en) | 2006-03-29 | 2008-03-27 | John Wayne Cancer Institute | Utility of high molecular weight melanoma associated antigen in diagnosis and treatment of cancer |
| EP2029999A2 (en) * | 2006-05-13 | 2009-03-04 | Dako Denmark A/S | Methods for flow cytometry analyses of cells without lysing subpopulations |
| ES2397971T3 (es) * | 2006-06-02 | 2013-03-12 | Pfizer Products Incorporated | Ensayo de células tumorales circulantes |
| WO2008111990A1 (en) * | 2006-06-14 | 2008-09-18 | Cellpoint Diagnostics, Inc. | Rare cell analysis using sample splitting and dna tags |
| EP2041299A4 (en) * | 2006-07-14 | 2010-01-13 | Aviva Biosciences Corp | METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE |
| WO2008014516A2 (en) * | 2006-07-28 | 2008-01-31 | Living Microsystems, Inc. | Selection of cells using biomarkers |
| CA2662859A1 (en) * | 2006-09-05 | 2008-03-13 | Veridex, Llc | Methods for ranking cellular images |
| US8244021B2 (en) | 2006-12-20 | 2012-08-14 | Ventana Medical Systems, Inc. | Quantitative, multispectral image analysis of tissue specimens stained with quantum dots |
| CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
| EP2155856A4 (en) | 2007-06-05 | 2013-06-26 | Nanopoint Inc | SYSTEMS AND METHODS OF CELL TRAY |
| WO2009038754A2 (en) | 2007-09-19 | 2009-03-26 | The Research Foundation Of State University Of New York | Gene expression signatures in enriched tumor cell samples |
| WO2009051734A1 (en) * | 2007-10-17 | 2009-04-23 | The General Hospital Corporation | Microchip-based devices for capturing circulating tumor cells and methods of their use |
| US8088715B2 (en) | 2007-11-13 | 2012-01-03 | Ikonisys, Inc. | Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope |
| US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
| US20110189670A1 (en) | 2008-07-07 | 2011-08-04 | Ruth L Katz | Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes |
| US9779213B2 (en) | 2008-07-25 | 2017-10-03 | Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud | System for evaluating a pathological stage of prostate cancer |
| US8324280B2 (en) | 2008-08-07 | 2012-12-04 | The University Of British Columbia | Treatment of prostate cancer with DDC inhibitor |
| CA2736178A1 (en) | 2008-09-05 | 2010-03-11 | Peter Kuhn | Methods for the detection of circulating tumor cells |
| CN107422127A (zh) | 2009-10-21 | 2017-12-01 | 斯克里普斯研究所 | 用非稀有细胞检测稀有细胞的方法 |
| CA2788245A1 (en) | 2010-01-27 | 2011-08-04 | Duke University | Biomarkers for circulating tumor cells |
| WO2011112581A1 (en) | 2010-03-08 | 2011-09-15 | Regents Of The University Of Minnesota | Androgen receptor isoforms and methods |
| TWI539158B (zh) | 2010-06-08 | 2016-06-21 | 維里德克斯有限責任公司 | 使用血液中之循環黑色素瘤細胞預測黑色素瘤病患之臨床結果的方法。 |
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| BR112013016708B1 (pt) | 2010-12-30 | 2021-08-17 | Foundation Medicine, Inc | Otimização de análise multigene de amostras de tumor |
| WO2012103025A2 (en) | 2011-01-24 | 2012-08-02 | Epic Sciences, Inc. | Methods for obtaining single cells and applications of single cell omics |
| CN103782170A (zh) | 2011-07-07 | 2014-05-07 | 斯克里普斯健康机构 | 分析心血管病症的方法及其用途 |
| US20130078667A1 (en) | 2011-09-22 | 2013-03-28 | Oscar B. Goodman | Methods for detecting and collecting circulating tumor cells |
| WO2013049926A1 (en) | 2011-10-06 | 2013-04-11 | UNIVERSITé LAVAL | PROGNOSTIC MARKERS OF INHERITED VARIATIONS IN THE 17β-HYDROXYSTEROID DEHYDROGENASE (HSD17B) GENES FOR PROSTATE CANCER |
| MX2014006884A (es) | 2011-12-09 | 2015-06-02 | Gerd Marienfeld | Aparato, sistema y metodo para identificar celulas tumorales circulantes. |
| DK2798355T3 (en) | 2011-12-30 | 2018-12-03 | Ventana Med Syst Inc | Automated analysis of circulating tumor cells |
| ES2724232T3 (es) | 2012-01-24 | 2019-09-09 | Pfizer | Procedimientos de detección de células tumorales circulantes positivas para 5T4 y procedimientos de diagnóstico de cáncer positivo para 5T4 en un sujeto mamífero |
| US10247725B2 (en) | 2012-06-01 | 2019-04-02 | Creatv Microtech Inc. | Capture, identification and use of a new biomarker of solid tumors in body fluids |
| US9766244B2 (en) | 2012-07-02 | 2017-09-19 | The General Hospital Corporation | Diagnosis and monitoring treatment of prostate cancer |
| US20140024024A1 (en) | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| WO2014047285A1 (en) | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| CA2889765C (en) | 2012-10-26 | 2021-06-22 | Minna D. BALBAS | Androgen receptor variants and methods for making and using |
| GB2531881B (en) | 2013-02-02 | 2017-12-13 | Univ Duke | Method of isolating circulating tumor cells |
| KR20220053691A (ko) | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| US20160266127A1 (en) | 2013-09-30 | 2016-09-15 | Peter Kuhn | Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients |
| WO2015073896A2 (en) | 2013-11-15 | 2015-05-21 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| US20170192003A1 (en) | 2013-12-03 | 2017-07-06 | The Scripps Research Institute | Compositions and methods for fluid biopsy of melanoma |
| WO2015103039A1 (en) | 2013-12-30 | 2015-07-09 | The Scripps Research Institute | Circulating tumor cell diagnostics for lung cancer |
| EA201691505A1 (ru) | 2014-01-27 | 2016-12-30 | Эпик Сайенсиз, Инк. | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) |
| WO2015112960A1 (en) | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc) |
| WO2015112955A1 (en) | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| ES2868077T3 (es) | 2014-01-30 | 2021-10-21 | Epic Sciences Inc | Diagnóstico mediante células tumorales circulantes para biomarcadores predictivos de la resistencia a las terapias selectivas del receptor de andrógenos (RA) |
| EA201691497A1 (ru) | 2014-01-31 | 2017-01-30 | Эпик Сайенсиз, Инк. | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| CN107250796B (zh) | 2014-09-25 | 2020-10-23 | 艾匹克科学公司 | 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断 |
| US20170242016A1 (en) | 2014-10-15 | 2017-08-24 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
| US20180155794A1 (en) | 2015-05-29 | 2018-06-07 | Epic Sciences, Inc. | Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc) |
| CN108603233A (zh) | 2015-11-03 | 2018-09-28 | 艾匹克科学公司 | 转移性疾病中循环肿瘤细胞(ctc)的单细胞基因组图谱分析以表征疾病异质性 |
| US20190025312A1 (en) | 2016-01-06 | 2019-01-24 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
-
2010
- 2010-10-20 CN CN201710186990.6A patent/CN107422127A/zh active Pending
- 2010-10-20 WO PCT/US2010/053431 patent/WO2011050103A1/en not_active Ceased
- 2010-10-20 JP JP2012535345A patent/JP6352588B2/ja active Active
- 2010-10-20 EP EP10825626.4A patent/EP2491395B1/en active Active
- 2010-10-20 EP EP15185229.0A patent/EP3045918B1/en active Active
- 2010-10-20 ES ES15185229.0T patent/ES2661735T3/es active Active
- 2010-10-20 CN CN2010800578539A patent/CN102782498A/zh active Pending
- 2010-10-20 EP EP17205552.7A patent/EP3385716A3/en not_active Withdrawn
- 2010-10-20 AU AU2010310688A patent/AU2010310688A1/en not_active Abandoned
- 2010-10-20 US US13/503,014 patent/US20120276555A1/en not_active Abandoned
- 2010-10-20 CN CN202210699103.6A patent/CN115060882A/zh active Pending
- 2010-10-20 ES ES10825626.4T patent/ES2556639T3/es active Active
- 2010-10-20 CA CA2778328A patent/CA2778328C/en active Active
-
2016
- 2016-05-26 AU AU2016203462A patent/AU2016203462B2/en active Active
- 2016-09-30 JP JP2016193236A patent/JP2017053860A/ja active Pending
-
2017
- 2017-05-22 US US15/601,696 patent/US20180100857A1/en not_active Abandoned
-
2018
- 2018-08-01 JP JP2018145154A patent/JP2018185339A/ja active Pending
- 2018-10-11 AU AU2018247290A patent/AU2018247290A1/en not_active Abandoned
-
2019
- 2019-01-18 US US16/252,472 patent/US10613089B2/en active Active
-
2020
- 2020-03-16 US US16/819,684 patent/US20210033612A1/en not_active Abandoned
-
2021
- 2021-04-13 AU AU2021202220A patent/AU2021202220A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021202220A1 (en) | 2021-05-06 |
| EP2491395A1 (en) | 2012-08-29 |
| ES2556639T3 (es) | 2016-01-19 |
| CN115060882A (zh) | 2022-09-16 |
| US20210033612A1 (en) | 2021-02-04 |
| WO2011050103A1 (en) | 2011-04-28 |
| ES2661735T3 (es) | 2018-04-03 |
| CN102782498A (zh) | 2012-11-14 |
| CA2778328C (en) | 2018-12-18 |
| JP2018185339A (ja) | 2018-11-22 |
| US20120276555A1 (en) | 2012-11-01 |
| AU2016203462A1 (en) | 2016-06-09 |
| CN107422127A (zh) | 2017-12-01 |
| EP3385716A2 (en) | 2018-10-10 |
| CA2778328A1 (en) | 2011-04-28 |
| EP3385716A3 (en) | 2019-01-09 |
| JP2017053860A (ja) | 2017-03-16 |
| AU2016203462B2 (en) | 2018-07-12 |
| EP2491395B1 (en) | 2015-09-16 |
| AU2018247290A1 (en) | 2018-11-01 |
| JP2013508729A (ja) | 2013-03-07 |
| US20190257834A1 (en) | 2019-08-22 |
| EP2491395A4 (en) | 2013-05-22 |
| JP6352588B2 (ja) | 2018-07-04 |
| US10613089B2 (en) | 2020-04-07 |
| EP3045918A1 (en) | 2016-07-20 |
| US20180100857A1 (en) | 2018-04-12 |
| EP3045918B1 (en) | 2017-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230085158A1 (en) | Method of using non-rare cells to detect rare cells | |
| US10613089B2 (en) | Method of using non-rare cells to detect rare cells | |
| US20140329917A1 (en) | Apparatus, system and method for identifying circulating tumor cells | |
| Marrinucci et al. | Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers | |
| US10254286B2 (en) | Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject | |
| US20080113350A1 (en) | Blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (FISH) | |
| WO2005116264A2 (en) | A blood test to monitor the genetic changes of progressive cancer using immunomagnetic enrichment and fluorescence in situ hybridization (fish) | |
| Garcia-Algar et al. | Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy | |
| EP3924733B1 (en) | Ccr5-based methods for predicting overall and progression free survival in subjects having cancer | |
| Slack et al. | Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis | |
| CN112763712B (zh) | 一组肿瘤诊断标志物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |